Literature DB >> 11374333

Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol.

K E Hutchison1, R Swift, D J Rohsenow, P M Monti, D Davidson, A Almeida.   

Abstract

RATIONALE: Haloperidol, a D2 antagonist, has been shown to moderate the effects of alcohol consumption on craving.
OBJECTIVE: The present study was designed to determine whether a single 5-mg dose of olanzapine (a D2/5-HT2 antagonist) would influence responses to alcohol cues or an alcohol challenge. It was hypothesized that olanzapine would attenuate cue-elicited urge to drink, attenuate the effects of alcohol consumption on urge to drink, and reduce the rewarding effects of alcohol.
METHODS: To test these hypotheses, 26 heavy social drinkers were randomized to receive either 5 mg olanzapine or placebo approximately 8 h before each of two experimental sessions. Participants consumed a moderate dose of alcohol in one experimental session and a non-alcohol control beverage in another session.
RESULTS: Results indicated that mere exposure to alcohol cues and consumption of alcohol increased urge to drink and that olanzapine attenuated these effects. Results also indicated that alcohol increased subjective stimulation and high while olanzapine did not moderate these effects.
CONCLUSIONS: These results suggest that olanzapine did not influence the rewarding effects of alcohol but did attenuate the effects of alcohol cues and an alcohol challenge on urge to drink.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374333     DOI: 10.1007/s002130000629

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.

Authors:  Raye Z Litten; Joanne B Fertig; Daniel E Falk; Megan L Ryan; Margaret E Mattson; Joseph F Collins; Cristin Murtaugh; Domenic Ciraulo; Alan I Green; Bankole Johnson; Helen Pettinati; Robert Swift; Maryam Afshar; Mary F Brunette; Nassima A-D Tiouririne; Kyle Kampman; Robert Stout
Journal:  Alcohol Clin Exp Res       Date:  2011-09-26       Impact factor: 3.455

Review 2.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

3.  Magnitude and duration of cue-induced craving for marijuana in volunteers with cannabis use disorder.

Authors:  Leslie H Lundahl; Mark K Greenwald
Journal:  Drug Alcohol Depend       Date:  2016-07-18       Impact factor: 4.492

4.  Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

Authors:  Robert Miranda; Stephanie S O'Malley; Hayley Treloar Padovano; Ran Wu; Daniel E Falk; Megan L Ryan; Joanne B Fertig; Thomas H Chun; Srinivas B Muvvala; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2020-05-25       Impact factor: 3.455

5.  Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder.

Authors:  Andrew Naglich; Bryon Adinoff; E Sherwood Brown
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

6.  Cue-induced craving for marijuana in cannabis-dependent adults.

Authors:  Leslie H Lundahl; Chris-Ellyn Johanson
Journal:  Exp Clin Psychopharmacol       Date:  2011-06       Impact factor: 3.157

7.  Differential patterns of alcohol consumption and dopamine-2 receptor binding in Wistar-Kyoto and Wistar rats.

Authors:  Irene Morganstern; Shanaz Tejani-Butt
Journal:  Neurochem Res       Date:  2010-08-03       Impact factor: 3.996

8.  Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.

Authors:  Robert Miranda; Hayley Treloar Padovano; Joshua C Gray; Stephanie E Wemm; Alexander Blanchard
Journal:  Addict Behav       Date:  2018-01-10       Impact factor: 3.913

Review 9.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

10.  Reactivity to cannabis cues in virtual reality environments.

Authors:  Patrick S Bordnick; Hilary L Copp; Amy Traylor; Ken M Graap; Brian L Carter; Alicia Walton; Mirtha Ferrer
Journal:  J Psychoactive Drugs       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.